Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is expected to report second quarter earnings results, after market close, on Tuesday 18th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.45 per share.
Looking ahead, the full year income are expected at $ 1.57 per share on the revenues of $ 456.64 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 360.00 million ~ $ 390.00 million
Click Here For More Historical Outlooks Of Supernus Pharmaceuticals, Inc.
Previous Quarter Performance
Supernus Pharmaceuticals, Inc. unfold income for the first quarter of $ 0.40 per share, from the revenue of $ 94.98 million. The quarterly earnings enlarged 17.65 percent compared with the same quarter last year. Street analysts expected Supernus Pharmaceuticals, Inc. to report income of $ 0.28 per share on revenue of $ 83.48 million for the first quarter. The bottom line results beat street analysts by $ 0.12 or 42.86 percent, at the same time, top line results outshined analysts by $ 11.50 million or 13.78 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Supernus Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of SUPN was $ 24.90, representing a 89.79 % increase from the 52 week low of $ 13.12 and a 16.47 % decrease over the 52 week high of $ 29.81.
The company has a market capital of $ 1.31 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”SUPN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The companys product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy.
